Compare GRFS & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRFS | PTCT |
|---|---|---|
| Founded | 1940 | 1998 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.3B |
| IPO Year | 2006 | 2013 |
| Metric | GRFS | PTCT |
|---|---|---|
| Price | $9.02 | $78.25 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 17 |
| Target Price | $10.15 | ★ $73.76 |
| AVG Volume (30 Days) | 551.2K | ★ 2.1M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 1.58% | N/A |
| EPS Growth | N/A | N/A |
| EPS | 0.64 | ★ 8.94 |
| Revenue | ★ $8,821,017,248.00 | $1,779,150,000.00 |
| Revenue This Year | $5.36 | $127.32 |
| Revenue Next Year | $5.15 | N/A |
| P/E Ratio | $17.99 | ★ $8.77 |
| Revenue Growth | 7.31 | ★ 97.54 |
| 52 Week Low | $6.19 | $35.95 |
| 52 Week High | $11.14 | $87.50 |
| Indicator | GRFS | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 53.16 | 56.79 |
| Support Level | $8.69 | $73.78 |
| Resistance Level | $9.22 | $80.20 |
| Average True Range (ATR) | 0.18 | 2.27 |
| MACD | 0.03 | -0.09 |
| Stochastic Oscillator | 64.15 | 74.26 |
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.